Abnormal Factor Ix Activity C5421579
Reduced Factor IX activity impairs blood clotting, characteristic of Hemophilia B. This inherited bleeding disorder primarily affects males and requires factor replacement therapy and comprehensive management.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Joint pain and swelling
Bleeding into the joints (hemarthrosis) causes sudden onset of pain, swelling, warmth, and limited range of motion, most commonly affecting knees, elbows, and ankles.
Seek immediate medical care if joint swelling is severe or accompanied by intense pain, as untreated joint bleeding can lead to permanent damage.
Muscle hematomas
Bleeding into muscles (muscle hematomas) causes painful swelling, tightness, and limited movement, commonly in thighs, calves, and buttocks.
Seek immediate emergency care for large or rapidly expanding muscle hematomas, especially in the thigh or buttocks, as they can cause compartment syndrome or significant blood loss.
Severe headache with confusion
Sudden severe headache, confusion, vision changes, or loss of consciousness may indicate potentially life-threatening intracranial hemorrhage (bleeding in the brain).
This is a medical emergency. Call emergency services immediately if experiencing sudden severe headache, confusion, weakness, or loss of consciousness.
Excessive bleeding from wounds
(hematologic)Cuts and wounds continue to bleed for an unusually long time due to impaired blood clotting from Factor IX deficiency.
Frequency: 90-95% of patients
Easy bruising
(dermatologic)Bruises (ecchymoses) appear frequently with minimal trauma due to bleeding under the skin from damaged blood vessels.
Frequency: 80-90% of patients
Frequent nosebleeds
(respiratory)Recurrent nosebleeds (epistaxis) occur spontaneously or with minimal irritation due to fragile blood vessels in the nasal lining.
Frequency: 40-60% of patients
Bleeding gums
(oral)Gums bleed easily during brushing, flossing, or eating, often persisting longer than normal due to impaired clot formation.
Frequency: 35-50% of patients
Blood in stool
(gastrointestinal)Bleeding in the digestive tract may appear as bright red blood in stool or black, tarry stools (melena) indicating upper GI bleeding.
Frequency: 10-20% of patients
Blood in urine
(genitourinary)Hematuria (blood in urine) may occur spontaneously or after minor trauma, appearing as pink, red, or brown-colored urine.
Frequency: 10-15% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Factor IX Replacement Therapy
Intravenous infusion of recombinant or plasma-derived factor IX concentrate to replace deficient clotting factor. This is the cornerstone of hemophilia B management, typically administered prophylactically or on-demand for bleeding episodes.
Joint Protection and Rehabilitation
Specialized physical therapy focusing on muscle strengthening, joint mobility, and prevention of hemarthrosis. Includes targeted exercises, hydrotherapy, and techniques to minimize joint damage from repeated bleeding.
Additional treatment options
Gene Therapy
Emerging gene therapy approach using viral vectors to deliver functional copies of the F9 gene, potentially providing long-term factor IX expression. Currently available through clinical trials and specialized treatment centers.
medicationAcute Bleeding Management (RICE Protocol)
Rest, Ice, Compression, and Elevation protocol for managing acute bleeding episodes at home. Combined with early factor replacement, this approach helps minimize tissue damage and accelerates recovery.
lifestyleComprehensive Monitoring Program
Regular monitoring including factor IX levels, inhibitor screening, joint assessments via ultrasound or MRI, and comprehensive blood work. Enables early detection of complications and treatment optimization.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Abnormal Factor Ix Activity C5421579?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
National Hemophilia Foundation. MASAC Recommendations on Products and Treatments for Hemophilia A and B. 2022.
World Federation of Hemophilia. Guidelines for the Management of Hemophilia. 3rd Edition. 2020.
Franchini M, Mannucci PM. Hemophilia B: pathophysiology, diagnosis, and treatment. J Blood Med. 2021;12:171-179.
Krust B, et al. Gene therapy for hemophilia B: Long-term results in clinical trials. N Engl J Med. 2021;384:2159-2170.
Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;387(10022):S0140-6736(16)32395-5.
American Society of Hematology. Clinical Practice Guidelines for Hemophilia B. Blood Adv. 2020;4(21):5656-5673.
Miller CH, et al. Complications of hemophilia: A systematic meta-analysis. Blood Rev. 2019;37:100583.
Hoffbrand AV, Steensma DP. Hoffbrand's Essential Haematology. 8th Edition. Wiley-Blackwell; 2019.
International Society on Thrombosis and Haemostasis. ISTH Guidance on Hemophilia Diagnosis and Management. J Thromb Haemost. 2021;19(9):2097-2108.
Srivastava A, et al. Hemophilia treatment guidelines: A consensus document by the World Federation of Hemophilia. Haemophilia. 2020;26(4):1-20.
Medication Comparisons
Compare medications used to treat Abnormal Factor Ix Activity C5421579. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy